The document describes a new ovulation monitor called the iOvo that uses microfluidic chips to precisely detect ovulation through measuring changes in saliva conductivity, a reliable marker of ovulation. It aims to provide more accurate predictions of ovulation 4-7 days in advance compared to other methods, and can confirm ovulation occurred. The founders have invested their own money and are seeking additional funding of around 10 million euros over 5 years for development, testing, patenting and production ramp-up. They expect to sell over 125,000 units in 5 years, reaching break-even in the third year and generating a 28% return on investment. The global market for fertility and ovulation products is growing and valued at around $4 billion annually.

1. Home Medical Device for
Family Planning Market:
Ovulation Monitor iOvo

2. Customer problems…
However, majority of modern ovulation prediction
methods lack either high predictive power or precision
and/or ability to confirm the ovulation
Millions of women around the globe use daily ovulation prediction tests to:
shorten time and
decrease costs for IVF
(in vitro fertilization)
procedures
raise the
chances
of conception
avoid undesired
pregnancies when
protection methods
cannot be used

3. It utilizes most precise ovulation
detection method with high
predictive power and the ability to
confirm the ovulation based on
contactless measurement of
saliva‘s conductivity change –
a reliable ovulation marker.
For this purpose we use originally
developed ultra-thin microfluidic
chips.
…and their solution
Microflexis iOvo
Ovulation Monitor

4. Advantages for customers and USPs
The device target
prediction power is
4 to 7 days before
the ovulation occurs
Accuracy –
more than
98%
In addition iOvo confirms that
ovulation indeed happened in
the cycle
Requires only 5ul of saliva
for measurement due to
originally developed re-usable
ultra-thin microfluidic chips
No annual extra costs
for a user in contrast to
other techniques
5ul

5. India, Brazil, China and Mexico are the most lucrative
markets for infertility devices and drugs and are
contributing to the sector’s rapid growth.
Market and its potential
Market size:
$1.68 billion of pregnancy and ovulation tests are sold
globally each year. The overall market of infertility drugs
and conception devices: $3.55 billion in 2010. Expected:
$4.77 billion by 2017. AGR: 4.3 percent from 2012 to 2017.
The market shows a growing migration from analogue
testing towards smarter digital devices to meet consumer
demand.

6. Management / Team
Karen Kalaydzhyan, PhD; founder,
CEO, responsible for product
development and production.
20 years of experience in academic
research (waveguide physics) and
business (medical devices).
Dmitri Ossipov, PhD; co-CEO,
responsible for business development.
10 years of business experience in
scientific and medical device market in
EMEA region. Before that 10 years of
research experience in Life Sciences
(USA, Germany).

7.  The founders invested own money for R&D and prototype production.
 Further required investment in 5 years:
 2 years = product development, patent pending, testing,
production and sales of pilot 500 kits) – 519.480,-€
 3 years = patent registration, production and sales of 120.000 kits)
– 9.534.600,-€
 Expected total sales within 5 years are 125.000 kits with turnover of
34.512.500,-€
 Expected total operating profit within 5 years is 24.458.420,-€.
 A break-even is reached within the third year.
 IRR=28%
Required investment and expected profit

8. Contact
Dr. Dmitri Ossipov
Vorstand | co-CEO
Mobile +49 176 996 288 08
dmitri.ossipov@microflexis.com
Microflexis UG
Lupinenweg 1
22549 Hamburg
Germany
www.microflexis.com
Danke sehr!
Thank you!
Спасибо!
どうもありがとう